Reuters logo
Bayer say VEGF Trap-Eye shows promise as mCNV treatment
June 6, 2013 / 6:46 AM / in 5 years

Bayer say VEGF Trap-Eye shows promise as mCNV treatment

FRANKFURT, June 6 (Reuters) - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).

Bayer co-develops the eye drug, also known as Eylea, with Regeneron.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below